Vermillion | GenomeWeb


CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.

The service business, which the company is calling Aspira IVD, generated $155,000 in revenue from two projects undertaken in the second quarter of 2016.

The revenues include the first sales from Vermillion's new IVD services business, Aspira IVD, which conducted two studies during the quarter.

Total revenues were down to $505,000 from $951,000 in the year-ago quarter as OVA1 test sales dropped to 2,265 from 3,783 in the first quarter of 2015.

The study found that in 122 patients with OVA1 results indicating high ovarian cancer risk, 109 had a gynecologic oncologist involved in their surgery.

The company plans to use the funds to build its new Trumbull, Connecticut facility, which will include laboratory and information technology infrastructure.

Vermillion performed 2,529 OVA1 tests in Q4 2015, down from 4,474 in Q4 2014, a drop the company attributed to transitioning testing from Quest Diagnostics.

The test is a second-generation version of the company's OVA1 proteomic test for assessing the likelihood of malignancy in pelvic masses planned for surgery.

The company aims to enroll 3,000 women in the registry, which it plans to use for research and development of tests to detect and manage pelvic masses.

The method is a potential competitor to proteomic tests like Vermillion's OVA1, but its developer noted that molecular data could further improve performance.


In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.